MedTrace Logo

Aflibercept 8 mg for nAMD: Early Anatomical and Functional Changes

NCT07074054 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2025-07-20

No results posted yet for this study

Summary

Neovascular age-related macular degeneration (nAMD) is one of the main causes of irreversible vision loss in older people worldwide.

the central role of vascular endothelial growth factor (VEFG) in the pathogenesis of nAMD has been extensively demonstrated. Since its introduction, intravitreal injection of targeted anti-VEGF antibodies has become the first-line treatment. Aflibercept 8 mg is a new formulation whose efficacy and safety as a new nAMD treatment has been demonstrated in the PULSAR study, emphasising its potential role in reducing the treatment burden in relation to the intended dosing intervals.

The aim of this study is to investigate early anatomical and functional changes in naïve nAMD patients treated with 8 mg aflibercept compared to patients treated with 2 mg aflibercept using OCT and MPOD, as potential parameters for functional outcome. To our knowledge, this is the first study to investigate these changes and the efficacy of aflibercept 8 mg as a potential fast-drying anti-VEGF treatment.

Conditions

  • Presence of Retinal Fluid
  • Changes in Macular Pigment Optical Density

Sponsors & Collaborators

  • Federico II University

    lead OTHER

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-15
Primary Completion
2024-04-15
Completion
2025-03-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07074054 on ClinicalTrials.gov